About BioNexus Gene Lab Corp. BGLC is an innovation-led life-sciences platform – bringing together precision diagnostics, cross-border expertise, and AI data development. Listed on Nasdaq, BGLC’s ...

Preclinical data presented at SAWC, the largest wound care conference in the United States, highlighted the in vitro performance of revyve ®, including inhibition of key proteases such as matrix ...

These two clearances mark an important step forward for Bioventus and represent a substantial growth opportunity as the Company looks to expand in the PNS market, which is currently estimated to be ...

A simultaneous webcast of the call may be accessed online from the Events & Presentations section of the Investor Relations page of the Company’s website at ...

“This partnership reflects our mutual commitment to advancing precision medicine for cancer,” said Dr. Bo Du, CEO of Genecast. “By integrating Paragon’s world-class target enrichment technologies into ...

LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only ...

Title: Results from a Phase 1 expansion cohort of solnerstotug (pH-selective anti-VISTA antibody) combined with cemiplimab in patients with advanced solid tumors resistant to prior PD- (L)1 therapy ...

VLTR-559, a long-acting anti-VEGF therapy, could reduce dosing frequency for the treatment of wet AMD to twice-yearly, as compared to every eight to twelve weeks for standard-of-care anti-VEGFs ...

Allen Institute to employ Iterative Mapping, Nautilus’ single-molecule proteomics method, to investigate connection between tau protein and Alzheimer’s disease • Agreement links the organizations’ ...

"It is important that we diligently execute on our digital treasury strategy designed to maximize our Bitcoin investment and maintain sufficient capital to provide the best-in-class, AI-driven digital ...

“We are thrilled that the New Zealand Patent Office recognized the innovative nature of BriaCell’s novel whole cell immunotherapy and its potential therapeutic applications for cancer patients,” said ...

Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Baseline in F-VASI and T-VASI at 3% Concentration Company Will Terminate Extension Phase ...